Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CPG10101 · 2 trials · 1 indication
| Arm | Type | Description |
|---|---|---|
| CPG10101 (0.2) + pegylated inteferon + ribavirin | EXPERIMENTAL | - |
| CPG10101 (0.5) + pegylated inteferon + ribavirin | EXPERIMENTAL | - |
| Pegylated interferon + ribavirin | ACTIVE_COMPARATOR | - |
| CPG10101 + pegylated interferon + ribavirin (rollover) | EXPERIMENTAL | - |
| CPG10101 | EXPERIMENTAL | - |
| CPG10101 + pegylated interferon | EXPERIMENTAL | - |
| CPG10101 + ribavirin | EXPERIMENTAL | - |
| CPG10101 + pegylated interferon + ribavirin | EXPERIMENTAL | - |
| Pegylated inteferon + ribavirin | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| CPG10101 | DRUG | CPG10101, subcutaneous, 0.2mg/kg, weekly, 24wks Pegylated interferon alfa-2b, subcutaneous, 1.5ug/kg, weekly, 24wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 24wks |
| Control | DRUG | Pegylated interferon alfa-2b, subcutaneous, 1.5 ug/kg, weekly, 12wks Ribavirin, oral, 800-1400mg/day (weight-based), daily, 12wks |
Inclusion Criteria: HCV positive subjects documented by serum HCV RNA concentration \> 100,000 IU/mL within 21 days of first study treatment Receipt of adequate previous PEG-IFN and RBV therapy for a minimum of 12 weeks (PEG-IFN alpha-2a doses of \> 180 μg/wk or PEG-IFN alpha-2b 1.5 µg/kg/wk and at...
CPG10101 is an investigational small molecule being studied for the treatment of chronic active hepatitis, specifically in patients with hepatitis C virus (HCV) infection. It has been evaluated in clinical trials as a combination therapy for relapsed HCV subjects and for non-responder HCV genotype 1 infected subjects.
CPG10101 is being developed by Pfizer, Inc., a biopharmaceutical company publicly traded under the ticker symbol PFE on the New York Stock Exchange.
CPG10101 is in Phase 2 clinical development. It has completed two clinical trials, including one Phase 1 study and one Phase 2 study. The drug remains investigational and has not been approved by regulatory authorities.
CPG10101 has been studied in two completed clinical trials. NCT00142103 was a Phase 1 study of CPG10101 combination therapy for relapsed hepatitis C virus subjects with 91 participants. NCT00277238 was a Phase 2 study in non-responder HCV genotype 1 infected subjects with 113 participants.
CPG10101 is a small molecule therapeutic. Its specific molecular target has not been disclosed in the available clinical trial information. The drug is being investigated as a combination therapy for chronic active hepatitis C virus infection.